Slone Partners Recruits CEO for Mirvie
November 11, 2026 – Life sciences-focused search firm Slone Partners has placed David Stern as CEO of Mirvie in South San Francisco, CA. “Maternal health is at an inflection point, and Mirvie is positioned to lead it,” said Leslie Loveless, managing partner and CEO of Slone Partners. “David pairs three decades of women’s health leadership with hands-on experience building commercial businesses, from product launch through a successful acquisition. We are proud to have partnered with the team at Mirvie to find the CEO who will bring the company’s exciting technological innovations to the expectant mothers who need it.”
“Founding and leading Mirvie has been the work of a lifetime, and I am delighted to pass the torch to David to accelerate and scale our commercial growth,” said Mirvie co-founder Maneesh Jain, who will transition from CEO to executive vice chair of the board. “The board and I are excited to partner with David as we work to change the trajectory of preterm birth and maternal health outcomes, which remain unacceptably poor for too many expectant mothers in America.”
Mr. Stern brings more than 30 years of women’s health leadership to Mirvie. Most recently, he was CEO of Kindbody, a national fertility clinic network and family-building benefits provider. Prior to that, Mr. Stern he served as CEO of Boston IVF, one of the largest fertility center providers in the U.S. As CEO of Symbiomix Therapeutics, he took the company from development through the commercial launch of Solosec, a breakthrough treatment for bacterial vaginosis, and successfully led its 2017 acquisition by Lupin Pharmaceuticals. Earlier in his career, he expanded and led the global fertility franchise at Merck Serono.
“Pregnancy is one of the last outdated frontiers of medicine that is still managed largely by one-size-fits-all guidelines,” said Mr. Stern. “What Maneesh and the team have built is rare: molecular insight into the biology of each pregnancy, a clinically validated test, established payer coverage, and growing demand from clinicians and patients. I’ve watched precision tools transform outcomes and the patient experience in fertility care, and I believe the technologies we are pioneering at Mirvie can do the same for pregnancy. It’s an honor to lead Mirvie into this next phase.”
Mirvie is a pregnancy health company focused on developing tools to better understand and predict pregnancy complications. The company’s proprietary Mirvie RNA Platform analyzes RNA signals in maternal blood to provide insights into pregnancy health and identify potential risks, including preeclampsia. The company is backed by top-tier investors including BlackRock, Decheng Capital, General Catalyst, GV, Khosla Ventures, Mayfield, and Portfolia.
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
In 2000, Adam Slone founded Slone Partners and acted as CEO from 2000 to 2016. He remains chairman today. His industry knowledge and extensive contacts have enabled Slone Partners to place thousands of executives and industry professionals. Today, Mr. Slone remains engaged with Slone Partners, with a specific focus in strategy, finance, M&A advisement, and business development in Boston and California.
Related: Slone Partners Recruits Chief Scientific Officer for Prolynx
Ms. Loveless has nearly 20 years of healthcare industry and executive search experience to Slone Partners. She joined the firm in 2007, became COO in 2014 and CEO in 2016. At Slone Partners, Ms. Loveless acts as the leader of the organization as well as the head of the executive search team. Her involvement with clients and candidates enables her to understand the key motivations of each. As CEO, Ms. Loveless’ focus extends to cultivating new business partnerships and expanding relationships with existing clients. Through her leadership, life sciences and biotechnology have emerged as the primary client base for Slone Partners.
Perspectum Search
Slone Partners also recently placed Warren Cresswell as CEO at Perspectum, an Oxford, England-based precision health company that delivers non-invasive solutions to accelerate drug development and improve patient outcomes in liver and cardiometabolic disease.
The Select Guide to America’s Top 250 Executive Search Firms
Hunt Scanlon Media proudly presents the Select Guide to America’s Top 250 Executive Search Firms.
This comprehensive online directory is your definitive resource for finding the best executive search firms to serve your talent needs.
Our guide is meticulously curated to connect you with leading firms that specialize in various industries and functions, ensuring you find the perfect match for your executive recruitment needs.
“Warren brings an exceptional combination of global leadership experience, commercial expertise, and deep knowledge across diagnostics and precision health,” said Ms. Loveless. “His proven ability to build and scale organizations will be tremendously valuable as Perspectum advances its innovative technologies and expands its impact on drug development and patient care. We are delighted to have helped bring Warren and the Perspectum team together.”
“Warren’s breadth of experience made him an outstanding fit for Perspectum at this important stage of the company’s evolution,” said Sona Stroud, senior partner at Slone Partners, who led the search. “He brings a unique combination of scientific and technology expertise with the commercial and operational leadership needed to translate innovation into meaningful clinical and business impact. It was a genuine pleasure working with Perspectum’s highly accomplished and thoughtful board and with Warren, who is an exceptional leader and person. Bringing the two together made this search particularly rewarding, and I am incredibly excited to see what they accomplish.”
Related: Slone Partners Recruits Chief Business Officer for 1910 Genetics
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
